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Introduction {#sec005}
============

During long-term total parenteral nutrition (TPN), high doses of certain water-soluble vitamins, such as those in the vitamin B family, do not pose a significant health risk. However, minerals are absorbed into the body unregulated and are not readily excreted during TPN. The accumulation of minerals, such as iron, is difficult to assess during TPN administration. One solution is to monitor blood mineral levels after administering a single dose; however, blood concentrations may not be an accurate reflection of iron accumulation in tissues.

Iron is the most abundant trace mineral in the body and plays a critical role in oxygen transport. When iron is low, a number of health issues arise, such as anaemia. Problems also occur when iron levels are high, and the Fenton reaction, which requires iron, may cause oxidative stress and lead to excessive lipid oxidation, DNA damage, and cell death by apoptosis, and carcinogenesis \[[@pone.0237104.ref001]\].

During intravenous iron administration, such as TPN, unlimited amounts of iron can be absorbed. This excess iron accumulates and leads to tissue damage. There are recommended safe doses of iron in Europe and the United States \[[@pone.0237104.ref002]\]. In patients with chronic inflammatory gastrointestinal disease, congenital problems in the digestive tract, or intestinal deficiencies secondary to surgery, iron is often administered intravenously.

Though uncommon in other counties, artificial nutrition, especially intravenous nutrition, is often the preferred treatment for ageing patients in Japan, particularly those who have problems with oral intake of food caused by dysphagia or dementia. Iron is often administered during TPN. Blended mineral preparations have been developed for this purpose, and it is therefore common for iron to be administered intravenously without strict monitoring of mineral levels.

Until the last century, long-term TPN was limited to specific patients, such as adults with short bowel syndrome. In Japan, TPN with a premixed blend of trace elements is still the treatment of choice for the management of older terminal patients. A study in Japan reported that, over the course of one year, half of the patients who died or were discharged received artificial nutrition and more than half received TPN on average for a period of 200 days \[[@pone.0237104.ref003]\]. However, the association between iron administration by TPN and iron deposition in the liver has never been examined.

The aim of the present study was to assess iron deposition in post-mortem liver samples isolated from older deceased patients to evaluate the influence of iron administration by long-term TPN.

Materials and methods {#sec006}
=====================

Study design and patient population {#sec007}
-----------------------------------

We conducted a retrospective observational study using data on blood indices, clinical history, and diagnosis prior to death for 187 patients, who were hospitalized and autopsied from 1999 to 2014 in Fukushimura Hospital, Aichi, Japan.

Clinical records and laboratory data {#sec008}
------------------------------------

From the clinical records, detailed data on intravenous iron administration, including volume, date, periods, and frequency, were assessed. Data on the number of days and the volume of iron administration were collected for one year prior to the patients' death and during the entire period of hospitalization. Laboratory data on iron metabolism, inflammatory factors, liver function, kidney function, and blood cell count were also collected. Several patients had hepatitis B or C virus antibodies, but did not have chronic hepatitis.

Blood sampling at autopsy and biochemical analysis {#sec009}
--------------------------------------------------

Dissections were performed immediately after death (if the patient died after midnight, the corpse was stored at 4°C until dissection), and blood was sampled from the subclavian vein before skin incision. Blood was centrifuged within 3 hours of collection and the serum was stored at −80°C until analysis. From these samples, aspartate aminotransferase (AST), alanine aminotransferase (ALT), unsaturated iron blood concentration (UIBC), serum iron, and ferritin were analyzed by Tosan Labo Center (Toyohashi, Japan), and albumin, pre-albumin, hepcidin, and interleukin-6 (IL-6) were analyzed by Hoken-Kagaku, Ltd. (Osaka, Japan). As shown in Tables [4](#pone.0237104.t004){ref-type="table"} and [5](#pone.0237104.t005){ref-type="table"}, the number of samples varied from patient-to-patient because the volume of blood was insufficient to analyze all parameters.

Liver tissue sampling and staining for iron {#sec010}
-------------------------------------------

Whole abdominal organs were removed according to standard dissection procedures. The liver was then separated from the abdominal tissue and immersed in buffered formalin for 1--2 weeks. If no lesions were observed, samples of the liver were obtained from segments 3 and 8, 15 mm^3^ in size. Then, according to standard protocols, the tissue was embedded in paraffin wax. The paraffin-embedded liver was sectioned into 4.5-micron slices, followed by deparaffinisation and rehydration. Prussian blue was used to stain iron histologically, while haematoxylin was used to stain nuclei.

The grading of iron deposition {#sec011}
------------------------------

Three investigators (H.A., K.T., H.O.), who specialize in the study of liver or liver pathology, evaluated the Prussian blue staining in each liver sample independently and recorded their findings on a custom data collection form. We verified the accuracy of these evaluations by comparing the forms of each investigator and resolving any discrepancies through discussion. The staining intensity was graded from a scale of 0 to V: Grade 0 (minimum grade), no staining; Grade I, small number of positive Kupffer cells; Grade II, moderate number of positive Kupffer cells; Grade III, most Kupffer cells are positive, with some positive hepatocytes, or no staining of Kupffer cells, but some positive hepatocytes; and Grade IV, large number of positive Kupffer cells and hepatocytes; Grade Ⅴ, most hepatocytes and Kupffer cells are positive.

Statistical analyses {#sec012}
--------------------

Data are reported as percentages for categorical variables, and as medians with interquartile range (IQR: 25%--75%) or as means with standard deviation (SD) for continuous variables. Comparisons were made between specimens with positive- and negative-iron staining and among grades of iron staining for each variable, using the χ^2^ test or Fisher's exact test for categorical variables, and Mann--Whitney *U* test, Kruskal--Wallis test, one-way analysis of variance, paired *t*-test, or Wilcoxon signed-rank test for continuous variables. Additional factors related to iron staining were determined using logistic regression analysis with independent variables, including gender and age, if p was \< 0.05 by univariate analysis. A step-wise selection method was used to select variables.

Data were analyzed using IBM SPSS Statistics version 25.0 (IBM, Armonk, NY, USA). For all analyses, statistical tests were two-tailed, and *p*\<0.05 was considered statistically significant.

Ethical statement {#sec013}
-----------------

The study was approved by the Ethics Committee of Fukushimura Hospital (approval number 353; Sept. 29, 2015). Informed consent from patients and their families was obtained for all human samples collected, with the knowledge that tissues taken during autopsy would be used for experimentation and analysis.

Results {#sec014}
=======

Clinical characteristics and cause of death {#sec015}
-------------------------------------------

The clinical characteristics of all patients according to positive or negative iron staining are shown in [Table 1](#pone.0237104.t001){ref-type="table"}.

10.1371/journal.pone.0237104.t001

###### Comparison of general characteristics of patients with and without iron staining.

![](pone.0237104.t001){#pone.0237104.t001g}

                                        Without iron staining (n = 92)   With iron staining (n = 95)   *p* value
  ------------------------------------- -------------------------------- ----------------------------- -----------
  **Sex**, Male, n (%)                  33 (35.9)                        54 (56.8)                     0.005
  **Age at death**, Median (IQR), y     86 (78--93)                      85 (77--95)                   0.513
  **Clinical history**                                                                                 
  Hospitalized transfusion              5 (5.4)                          6 (6.3)                       1.000
  Transfusion                           3 (3.3)                          2 (2.1)                       0.679
  Operation                             23 (25.0)                        37 (38.9)                     0.044
  Trauma                                13 (14.1)                        10 (10.5)                     0.509
  Fracture                              23 (25.0)                        11 (11.6)                     0.022
  **Underlying disease or condition**                                                                  
  HBV ab+                               2 (2.2)                          3 (3.2)                       1.000
  HCV ab+                               4 (4.3)                          7 (7.4)                       0.537
  Cerebral infarction                   35 (38.0)                        24 (25.3)                     0.083
  Malignant neoplasm                    24 (26.1)                        21 (22.1)                     0.608
  Liver cirrhosis                       2 (2.2)                          3 (3.2)                       1.000
  Diabetes mellitus                     15 (16)                          9 (9.5)                       0.193
  Hypertension                          25 (27.2)                        16 (16.8)                     0.112
  Dementia                              41 (44.6)                        47 (49.5)                     0.559

IQR, interquartile range; HBV ab+, hepatitis B virus antibody positive; HCV ab+, hepatitis C virus antibody positive.

Among the iron-positive patients, the vast majority were male (p = 0.005) and were more likely to have a history of surgery (p = 0.044). The most frequent cases of surgery were for femoral fracture (10 cases), female reproductive ailments (7 cases) or digestive system disorders outside of the intestine (7 cases). There were two cases of bowel resection for colorectal cancer, and both patients had an iron deposition grade of I or II in the liver. Patients with a history of fractures, other than a femoral fracture, were more likely to be iron-negative. There were no other factors significantly associated with iron deposition in the clinical history or diagnosis.

In [Table 2](#pone.0237104.t002){ref-type="table"}, the cause of death at autopsy is compared with our findings on iron deposition. No correlation was found between cause of death and liver iron deposition.

10.1371/journal.pone.0237104.t002

###### Comparison of cause of death in patients with and without iron staining.
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                             Without iron staining (n = 92)   With iron staining (n = 95)   p-value
  -------------------------- -------------------------------- ----------------------------- ---------
  Heart failure              25 (27.2)                        15 (15.8)                     0.074
  Cardiovascular disease     2 (2.2)                          4 (4.2)                       0.683
  Digestive organ disorder   3 (3.3)                          1 (1.1)                       0.363
  Malignant neoplasm         11 (12.0)                        8 (8.4)                       0.425
  Pneumonia                  23 (25.0)                        29 (30.5)                     0.419
  Respiratory failure        11 (12.0)                        18 (18.9)                     0.227
  Renal failure              3 (3.3)                          5 (5.3)                       0.721
  Liver failure              2 (2.2)                          3 (3.2)                       1.000
  Sepsis                     5 (5.4)                          2 (2.1)                       0.273
  Multi-organ failure        5 (5.4)                          10 (10.5)                     0.282
  Sudden death               5 (5.4)                          3 (3.2)                       0.492

Iron deposition in liver {#sec016}
------------------------

Of the 187 cases evaluated, more than half (95) had positive Prussian blue staining, indicative of iron accumulation. Moreover, in 128 of the cases (68%), patients had been receiving TPN at the time of death. The staining patterns are shown in [Fig 1](#pone.0237104.g001){ref-type="fig"}.

![Prussian blue staining in autopsied liver.\
a, Grade 0 (no staining). b, Grade I (small number of positive Kupffer cells). c, Grade II (moderate number of positive Kupffer cells). d, Grade III (most Kupffer cells are positive, with some positive hepatocytes). e, Grade III (no staining of Kupffer cells, but some positive hepatocytes). f, Grade IV (large number of positive Kupffer cells and hepatocytes). g, Grade V (most hepatocytes and Kupffer cells are positive).](pone.0237104.g001){#pone.0237104.g001}

The distribution of the number of cases with iron staining was 92 in Grade I ([Fig 1B](#pone.0237104.g001){ref-type="fig"}), 27 in Grade II ([Fig 1C](#pone.0237104.g001){ref-type="fig"}), 14 in Grade III ([Fig 1D](#pone.0237104.g001){ref-type="fig"} or [1E](#pone.0237104.g001){ref-type="fig"}), and 6 in Grade IV ([Fig 1F](#pone.0237104.g001){ref-type="fig"}), and 4 in Grade V ([Fig 1F](#pone.0237104.g001){ref-type="fig"}). Only one sample, from a patient who had been diagnosed with haemochromatosis (details unknown), had an extremely high level of staining (iron-positive hepatocytes and almost all Kupffer cells were positive) and was classified as Grade V ([Fig 1G](#pone.0237104.g001){ref-type="fig"}).

Nutritional administration {#sec017}
--------------------------

[Table 3](#pone.0237104.t003){ref-type="table"} compares the modes of nutritional administration and the status of TPN with positive or negative iron staining in patients.

10.1371/journal.pone.0237104.t003

###### Conditions of artificial nutritional support and iron administration in post-mortem liver with or without iron staining.
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                                                                           Without iron staining (n = 92)   With iron staining (n = 95)   *p* value
  ------------------------------------------------------------------------ -------------------------------- ----------------------------- -----------
  **Route of artificial nutrition at death**                                                                                              \<0.001
  NG                                                                       2 (2.2)                          0 (0.0)                       
  PEG                                                                      5 (5.4)                          2 (2.1)                       
  Oral intake                                                              3 (3.3)                          0 (00)                        
  TPN                                                                      50 (54.3)                        78 (82.1)                     
  PPN                                                                      19 (20.7)                        14 (14.7)                     
  Unknown                                                                  13 (14.1)                        1 (1.1)                       
  **Conditions of iron administration**, median (IQR)                                                                                     
  Number of days of TPN in the year before death, days (n = 140)           41 (14--104)                     97 (31--243)                  0.004
  Volume of iron administered in the year before death, μmol (n = 132)     805 (166--2231)                  13512 (245--3421)             0.222
  Number of days of iron infusion during hospitalization, days (n = 161)   46 (22--130)                     99 (32--236)                  0.038
  Total volume of iron infused during lifetime (μmol) (n = 157)            1155 (315--2887)                 1907 (315--4541)              0.220

NG, naso-gastric tube; PEG, percutaneous endoscopic gastrostomy; TPN, total parenteral nutrition; PPN, partial parenteral nutrition.

The percentage of patients receiving TPN versus all other modes of artificial nutrition was significantly higher in the iron-positive group (82.1%; *p*\<0.001) compared with the iron-negative group. The number of patients with iron-positive staining who had been receiving TPN at the time of death was 128, although as many as 140 patients had received artificial nutrition in the year before death.

The number of days of TPN administration was significantly higher in the iron-positive group compared with the iron-negative group both in the year before death (*p* = 0.004) and during hospitalization (*p* = 0.038). However, the volume of TPN was not significantly different between the groups in the year before death (*p* = 0.222) or during the hospitalization (*p* = 0.220).

Biochemical analysis of blood {#sec018}
-----------------------------

Blood chemistry (iron-related factors, hepatobiliary enzymes), hepcidin, IL-6, albumin, and prealbumin were measured from blood collected at the time of autopsy. UIBC was significantly higher in the iron-negative group, and ferritin and iron were significantly higher in the iron-positive group ([Table 4](#pone.0237104.t004){ref-type="table"}).

10.1371/journal.pone.0237104.t004

###### Laboratory indices in patients with and without iron staining using post-mortem serum.
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  -------------------------------------------------------------------------------------------------------
  \                            Without iron staining (n = 92)   With iron staining (n = 95)   *p* value
  Median (IQR)                                                                                
  ---------------------------- -------------------------------- ----------------------------- -----------
  AST (IU/L) (n = 169)         84.0 (41.0--291.0)               70.5 (36.0--190.0)            0.397

  ALT (IU/L) (n = 169)         28.5 (7.8--103.8)                29.0 (9.0--48.5)              0.382

  γ-GTP (IU/L) (n = 169)       40.0 (20.0--61.0)                34.0 (20.0--75.8)             0.963

  LDH (IU/L) (n = 169)         270.0 (206.0--537.3)             321.0 (150.5--394.0)          0.150

  ALP (IU/L) (n = 169)         335.0 (251.0--596.0)             379.5 (250.5--521.0)          0.756

  UIBC(μg/dL) (n = 171)        94.0 (50.0--121.0)               40.5 (24.0--70.3)             \<0.001

  Ferritin (ng/mL) (n = 171)   637.0 (266.0--1429.0)            1281.5 (708.8--2518.5)        \<0.001

  Fe (μg/dL) (n = 171)         49.0 (39.0--75.0)                64.0 (45.3--94.8)             0.002

  Hepcidin (n = 49)            50.7 (34.2--151.9)               118.9 (50.1--176.6)           0.169

  IL-6 (n = 49)                7.3 (5.7--9.0)                   7.2 (6.2--9.1)                0.909

  Pre-alb (n = 169)            5.9 (3.3--10.0)                  4.2 (2.6--7.8)                0.844

  alb (n = 171)                1.8 (1.4--2.2)                   1.5 (1.2--1.9)                0.440
  -------------------------------------------------------------------------------------------------------

IQR, interquartile range; AST, aspartate transaminase; ALT, alanine transaminase; γ-GTP, γ-glutamyl transpeptidase; ALP, alkaline phosphatase; UIBC, unsaturated iron binding capacity; Fe, serum iron; IL-6, interleukin 6; pre-alb, pre-albumin; alb, albumin.

The blood data from three patients in the iron-positive group was compared and is shown in [Table 5](#pone.0237104.t005){ref-type="table"}.

10.1371/journal.pone.0237104.t005

###### Laboratory findings in post-mortem serum according to iron staining grade.
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                               Grade of iron staining                                                     
  ---------------------------- ------------------------ ------------------------ ------------------------ ---------
  AST (IU/L) (n = 169)         84.0 (41.0--291.0)       93.5 (40.0--292.3)       53.0 (31.5--141.0)       0.106
  ALT (IU/L) (n = 169)         36.0 (11.0--104.0)       30.0 (12.0--69.3)        23.0 (12.0--69.3)        0.575
  γ-GTP (IU/L) (n = 169)       40.0 (20.0--62·0)        37.5 (19.0--75.8)        30.0 (12.0--69.3)        0.995
  LDH (IU/L) (n = 169)         380.0 (220.0--767.0)     392.5 (253.0--548.8)     281.5 (166.0--460.3)     0.043
  ALP (IU/L) (n = 169)         335.0 (251.0--460.3)     380.0 (259.8--515.0)     374.5 (248.3--656.5)     0.952
  UIBC (μg/dL) (n = 171)       94.0 (50.0--121.0)       51.0 (27.0--74.5)        25.0 (24.0--65.0)        \<0.001
  Ferritin (ng/mL) (n = 171)   637.0 (266.0--1429.0)    1134.0 (550.5--2477.0)   1434.0 (780.0--2524.0)   \<0.001
  Fe (μg/dL) (n = 171)         49.0 (39.0--75.0)        59.0 (41.5--75.0)        73.0 (57.0--103.0)       0.001
  Hepcidin (g/dL) (n = 49)     50.7 (34.2--151.9)       125.3 (50.1--157.7)      111.7 (48.1--188.1)      0.377
  IL-6 (pg/mL) (n = 49)        7.3 (5.7--9.0)           7.7 (6.6--8.5)           7.0 (5.9--9.4)           0.477
  Pre-alb (n = 169)            5.9 (3.3--10.0)          3.7 (2.5--6.4)           4.8 (2.6--8.9)           0.040
  alb (n = 171)                1.8 (1.4--2.2)           1.5 (1.2--2.0)           1.5 (1.2--1.8)           0.004

IQR, interquartile range; AST; Aspartate transaminase, ALT; Alanine transaminase, γ-GTP; γ-glutamyl transpeptidase, ALP; alkaline phosphatase, UIBC; Unsaturated iron binding capacity, Fe; Serum iron, IL-6; Interleukin 6, Pre-alb; pre-albumin, alb; albumin.

UIBC was significantly lower in cases with stronger iron deposition (p\<0.001), and ferritin (p\<0.001) and iron (p = 0.001) were significantly higher in cases with stronger iron deposition.

Factors associated with iron staining {#sec019}
-------------------------------------

Logistic regression analysis revealed that male sex (odds ratio \[OR\], 4.119; 95% confidence interval \[CI\], 1.773--9.566) and iron in post-mortem serum (OR, 1.025; 95% CI, 1.010--1.041) were factors associated with iron staining if the volume of TPN was included in the adjusted variables ([Table 6](#pone.0237104.t006){ref-type="table"}). If the volume of TPN was excluded from this analysis, UIBC in post-mortem serum (OR, 1.014; 95% CI, 1.003--1.022) and administration of TPN (OR, 3.586; 95% CI, 1.664--7.732) were factors significantly associated with iron staining ([Table 6](#pone.0237104.t006){ref-type="table"}).

10.1371/journal.pone.0237104.t006

###### Factors associated with iron staining using logistic regression models.
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                              coefficient   SE      *P* value   OR      95% CI
  --------------------------- ------------- ------- ----------- ------- --------------
  **Model 1**                                                           
  Constant                    -1.556        0.537                       
  Male gender                 1.416         0.430   0.001       4.119   1.773--9.566
  Iron in post-mortem serum   0.025         0.008   0.001       1.025   1.010--1.041
  **Model 2**                                                           
  Constant                    -2.688        0.561                       
  UIBC in post-mortem serum   0.014         0.004   0.000       1.014   1.006--1.022
  TPN                         1.277         0.392   0.001       3.586   1.664--7.732

SE, standard error; OR, odds ratio; CI, confidence interval; UIBC, unsaturated iron binding capacity; TPN, total parenteral nutrition

Adjusted covariance of Model 1: age, gender, history of operation, history of fracture, TPN, partial parenteral nutrition (PPN), number of days of TPN and volume of iron during the year prior to the patients' death, number of days of TPN and amount of iron during the entire period of hospitalization, serum UIBC, serum ferritin, and serum iron.

Covariance of Model 2: age, gender, history of operation, history of fracture, TPN, PPN, number of days of TPN for one year prior to the patients' death and during the entire period of hospitalization, serum UIBC, serum ferritin, and serum iron, serum UIBC, serum ferritin, and serum iron.

Discussion {#sec020}
==========

The present study revealed that iron administration by long-term TPN significantly affected iron deposition in the liver of older patients, even at the minimum recommended iron dosage. This is the first study to demonstrate an association between iron administration and iron deposition in post-mortem liver specimens.

The average adult loses approximately one mg of iron per day, mainly because of cell turnover \[[@pone.0237104.ref004]\]. About two-thirds of iron is lost in the gastrointestinal tract, and one-third is lost from the skin. Iron loss in urine and sweat is minimal because there is no physiological mechanism for iron excretion.

With oral intake of iron, about two-thirds is absorbed as haeme via haeme carrier protein 1 (HCP1) \[[@pone.0237104.ref005]\]. The remaining one-third of iron is absorbed as non-haeme Fe^3+^, which is reduced by duodenal cytochrome b (Dcytb) \[[@pone.0237104.ref006], [@pone.0237104.ref007]\] to Fe^2+^, and then is absorbed by divalent metal transporter 1 (DMT1) \[[@pone.0237104.ref007], [@pone.0237104.ref008]\]. This absorption mechanism is thought to be restricted and adjusted based on the body's existing iron levels. However, because iron absorption also occurs in the large intestine, there is a risk of iron accumulation, even with oral intake \[[@pone.0237104.ref009]\]. If oral consumption of iron exceeds 100 mg/day, iron overload (Bantu siderosis) can occur \[[@pone.0237104.ref012]\].

In patients with difficulty consuming iron orally, long-term TPN rarely leads to iron deficiency, and the American Society for Parenteral and Enteral Nutrition (ASPEN) 2002 guidelines \[[@pone.0237104.ref010]\] do not recommend upper and lower limits for the amount of iron infused per day. However, several studies have reported that in adults and children receiving TPN, 29%--55% \[[@pone.0237104.ref011]\] and 22% \[[@pone.0237104.ref012]\], respectively, experienced anaemia. The ASPEN guidelines were therefore revised to recommend an iron dose of 1--5 mg/day \[[@pone.0237104.ref002]\]. Similarly, the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines recommend a dose of 1--1.2 mg/day of iron for parental nutrition \[[@pone.0237104.ref013]\]. In Japan, the recommended dose of iron with TPN is 2 mg (35 μmol)/day, and the iron concentration in blended mineral preparations is 2 mg per ampoule (A). To avoid iron overload, a new formula of TPN using an all-in-one bag has an iron dose of 1.1 mg/bag, regardless of volume or calories. However, these recommendations are based on predicted consumption, transitions in serum iron, and haemoglobin levels. Although the data are no longer current, a report from Japan found that no side effects were caused by the administration of 10 mg ferric chloride (about 2 mg of iron) per day in a 54-year-old male receiving TPN for four years \[[@pone.0237104.ref014]\].

The criteria for iron overload are based on ferritin levels, according to the World Health Organization in 2013 \[[@pone.0237104.ref015]\]. However, iron overload is often assessed by haemoglobin and serum iron levels. Even ageing anaemic patients with adequate ferritin levels, but in a state of chronic inflammation, may be inadvertently administered iron \[[@pone.0237104.ref016]\]. It is unclear whether the amount of iron administered is appropriate, but there are several reports of iron overload using MRI and liver fibrosis markers in cases of thalassemia \[[@pone.0237104.ref017], [@pone.0237104.ref018]\]. Furthermore, in hepatitis C cases, associations of iron overload in liver biopsies have also been investigated \[[@pone.0237104.ref017]\]. However, these data apply to specific diseases, and do not specify cases of parenteral iron infusion.

Iron deposition in the liver has not been previously studied in autopsied patients, and in our study, intravenous iron administration has been our focus. Because our study used retrospective data from clinical records, the exact daily doses and dosing periods could not be precisely assessed. In contrast, it is impossible to perform prospective studies on human liver tissue. In our case, the maximum iron dose was estimated from the administration of an integrated trace element preparation, 1 A (ferric chloride 9.460 mg/Fe 35 μmol or 2 mg), present in only a few cases. Most patients were given 2--3 A/week, or ferric chloride 4.73 mg/Fe 17.5 μmol (1 mg)/day in a pre-packaged blend. This amount adheres to the lower recommended limit. Based on our assessment of the medical records, the number of days, and total amount of iron administration, there were no cases of patients receiving more than 35 μmol of iron/day. In this study, haemoglobin level of many cases was a little below the normal level. But none of the cases had intensive intravenous iron administration for therapeutic purposes under the diagnosis of iron deficiency anemia. In almost all cases, an all-in-one bag TPN formulation containing a mineral component (iron dose of 1.1 mg/bag) was used for daily iron supplementation.

In this study, over half of the patients were positive for iron deposits in the liver. Prussian blue staining \[[@pone.0237104.ref019]\] highlights the iron-storage complex haemosiderin, non-haeme iron (Fe^3+^), and severe iron deposition in haemosiderosis \[[@pone.0237104.ref020]\]. This form of iron, Fe^3+^, is involved in the generation of free radicals by the Fenton reaction, which causes severe cellular and tissue damage, thereby contributing to fibrosis of the liver \[[@pone.0237104.ref021]\]. In a study of hepatitis C, a strong correlation has been found between iron deposition and fibrosis of the liver \[[@pone.0237104.ref022]\].

First, it is worth noting that males showed more iron deposition than females ([Table 1](#pone.0237104.t001){ref-type="table"}). This tendency has been described previously in hepatitis C patients in a study that found that liver iron accumulation was associated with the male sex, reflected by high serum iron and ferritin levels \[[@pone.0237104.ref023]\].

With iron administration and iron deposition in the liver, it is impossible to know the exact lifetime dose of iron. In our paper, we focused on the intake of iron by infusion, although there are also reported cases in which secondary haemochromatosis is caused by oral iron administration \[[@pone.0237104.ref024]\]. Additionally, regardless of the aetiology, iron-loading is frequently observed in chronic liver diseases, such as iron overload syndrome, hereditary haemochromatosis, viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and diabetes \[[@pone.0237104.ref021]\]. Abnormalities in iron metabolism have also been reported in patients with acquired immunodeficiency syndrome (AIDS) \[[@pone.0237104.ref025]\].

In this study, no patients were previously diagnosed with liver disease, although there were multiple cases of organ and liver failure at the time of death. In assessing the route of nutritional administration, the percentage of patients on TPN (82.1%) was significantly higher in the iron-positive group. Additionally, this group appeared to have a much higher volume of iron administered in the year before death compared with the iron-negative group. The maximum amount of iron administered, 3,535 μmol/year, was nearly equivalent to 10 μmol (0.57 mg)/day and less than the recommended dose. Although it was impossible to obtain the exact dosage, the possibility of iron deposition in the liver cannot be eliminated in long-term TPN patients. We recommend that the amount of intravenous iron administered be carefully evaluated, especially in older adult patients.

Many physicians still prescribe iron supplementation based solely on haemoglobin and serum iron indices. However, ferritin should also be checked in all patients, and not only in those with chronic kidney disease, as previously mentioned in reviews \[[@pone.0237104.ref026]\]. In our post-mortem blood samples, ferritin levels correlated strongly with liver iron deposition. However, the ferritin level was higher in some patients without iron staining than those with iron staining. In patients with chronic inflammatory diseases, higher ferritin levels are more likely to be caused by problems in iron metabolism whether there is a lot of iron or not. That is, regardless of the accumulation of iron \[[@pone.0237104.ref027]\]. In the present study, all patients had been hospitalized with terminal diseases, and their median age was 85 years. Among some of these patients, the ferritin level may not be related to iron deposition in the liver. In contrast, UIBC was significantly lower, and serum iron and ferritin were significantly higher in the iron-positive group. No association was found with hepcidin and IL-6, which are key factors in iron metabolism.

Our study showed that long-term iron infusion can lead to iron deposition in the liver. It is possible that iron is deposited in other tissues as well, although we did not investigate this. We found that iron deposition in the liver was strongly correlated with ferritin levels. Therefore, ferritin should be considered a good marker for iron.

The recommended dose of iron in Japan is slightly higher than that in Europe and the United States. In this study, iron deposition in the liver was examined, and chronic intravenous iron administration was associated with tissue deposition of iron, even at less than 10 μmol (0.57 mg)/day. This suggests that tissue iron deposition occurs in long-term TPN patients, even when the daily dose of iron is less than the recommended amount.

The limitations of the present study are associated with its retrospective design. Although we are the first to demonstrate a strong correlation between the long-term use of TPN and iron deposition in the liver, we do not fully understand the cause or mechanism of iron accumulation. Moreover, we were unable to obtain accurate data on the dosage of intravenous iron administration before hospital admission. Nevertheless, our results provide important information for physicians caring for older patients using long-term TPN.

Conclusions {#sec021}
===========

Chronic intravenous administration of iron was associated with iron deposition in the liver, even in patients receiving the minimum recommended amount. Therefore, in long-term TPN patients, iron dose should be carefully considered. The results of the present study highlight the value of analyzing and evaluating post-mortem samples to potentially improve the future treatment and care of elderly patients.
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Point-by-point response to reviewers' comments

Thank you very much for your time and valuable feedback. We have carefully considered your comments and suggestions and have revised our manuscript accordingly. We have included our responses to the reviewers' comments below. For clarity, the reviewer's comments are shown in blue and our responses are shown in black.

Reviewer reports:

Reviewer \#1:

In the present study, authors investigated iron deposition in autopsied live specimens from patients receiving intravenous iron infusion. They concluded that iron administration by long-term total parenteral nutrition (TPN) affected the iron deposition in liver. Although this is a well-written paper that presents interesting data, there are several drawbacks in the manuscript

Major points

1\) To the best of my knowledge, this is the first study to demonstrate the association between iron administration and iron deposition in liver specimens. I think the authors should place more emphasis on the point in both the background and discussion section.

Thank you very much for your kind comment and pointing out the significance of our work. Yes, we also believe that this is the first study demonstrating the association between iron administration and iron deposition in the liver, and we have added statements to the Introduction and Discussion sections emphasising this point.

P. 5; Lines 61-62.

However, the association between iron administration by TPN and iron deposition in the liver has never been examined.

P. 15; Lines 241-242.

This is the first study to demonstrate an association between iron administration and iron deposition in post-mortem liver specimens.

2\) Regrettably, the authors simply indicated conditions of iron administration in terms of with or without iron staining (Table 3), I think it would be useful if the authors gave more data according to the iron staining grade.

Thank you very much for this important suggestion. As you mentioned in comment \#4, however, the grading of iron staining was variable, even among our expert observers. For this reason, we used positive or negative iron staining as the principal comparison in Tables 1--4. However, in Table 5, we have presented our laboratory findings in post-mortem serum according to the grade of iron staining. We hope this is sufficient.

3\) The authors state that clinical data on iron administration including volume, data, periods and frequency were assessed in the method section. Analysis of the frequency of iron administration should be added to the result section.

As suggested, we have added the method of data collection for iron administration to the methods section and have modified our explanation of the data in the Results section.

P. 5; Lines 75-77.

Data on the number of days and the volume of iron administration were collected for one year prior to the patients' death and during the entire period of hospitalization.

P. 12; Lines 188-192.

The number of days of TPN administration was significantly higher in the iron-positive group compared with the iron-negative group both in the year before death (p = 0.004) and during hospitalization (p = 0.038). However, the volume of TPN was not significantly different between the groups in the year before death (p = 0.222) or during the hospitalization (p = 0.220).

4\) Page 7 Line 103: 'At least (three independent investigators)' is unclear. Can the number of investigators differ according to each cases? Moreover, was there an intraobserver error? These points should be explained.

The "three independent investigators" are co-authors of the manuscript. We have identified the investigators using their initials and have added an explanation of how we minimised interobserver error.

P. 7; Line 104-108.

Three investigators (H.A., K.T., H.O.), who specialize in the study of liver or liver pathology, evaluated the Prussian blue staining in each liver sample independently and recorded their findings on a custom data collection form. We verified the accuracy of these evaluations by comparing the forms of each investigator and resolving any discrepancies through discussion.

5\) Bowel resection could be related to the iron overload. In the table 1, iron-positive patients were more likely to have a history of surgery. The authors should explain in more detail the data and further discussion needs to be included to address the point.

P. 9; Lines 144-149.

The most frequent cases of surgery were for femoral fracture (10 cases), female reproductive ailments (7 cases) or digestive system disorders outside of the intestine (7 cases). There were two cases of bowel resection for colorectal cancer, and both patients had an iron deposition grade of I or II in the liver. Patients with a history of fractures, other than a femoral fracture, were more likely to be iron-negative.

6\) What is the best predictable marker for iron deposition in terms of the iron staining in autopsied liver specimens? I think the quality of this paper could be enhanced by adding the data.

In the Results section, we have added an analysis of predictable markers for iron deposition using logistic regression models. These results are presented in Table 6 with the subheading, "Factors associated with iron staining."

P. 12; Lines 218-224.

Logistic regression analysis revealed that male sex (odds ratio \[OR\], 4.119; 95% confidence interval \[CI\], 1.773-9.566) and iron in post-mortem serum (OR, 1.025; 95% CI, 1.010-1.041) were factors associated with iron staining if the volume of TPN was included in the adjusted variables. If the volume of TPN was excluded from this analysis, UIBC in post-mortem serum (OR, 1.014; 95% CI, 1.003-1.022) and administration of TPN (OR, 3.586; 95% CI, 1.664-7.732) were factors significantly associated with iron staining.

7\) There are quite some odd wording and use of grammar. English of the manuscript has to be checked by a native speaker.

Our manuscript was revised by professional scientific editors who are native English speakers.

Minor points

1\) In the abstract section, the authors should definitely describe the purpose of the study.

We have added the purpose of the study to the abstract.

P. 2; Lines 6-8.

The aim of the study was to assess the influence of iron administration by long-term TPN on iron deposition in post-mortem liver samples isolated from older deceased patients.

2\) In the abstract section, storage condition of the sample was unnecessary.

We have revised this sentence.

P. 2; Lines 15-17.

Samples were collected for the measurement of unsaturated serum iron, serum iron, albumin, prealbumin, hepcidin, and IL-6 concentrations.

3\) Page11, Line167; '81.2%' should be changed into '82.1%'.

We have corrected 81.2% to 82.1%.

P. 11; Line 184.

......in the iron-positive group (82.1%; p\<0.001)

Reviewer \#2:

1\. Line 275, "3.54 μmol/year or 10 μmol (1 mg)/day"

Why iron amount per year is lower than that per day?

Thank you for pointing this out. It was a mistake, and we have corrected it in the text.

P. 19; Lines 316-317.

The maximum amount of iron administered, 3,535 μmol/year, was nearly equivalent to 10 μmol (0.57 mg)/day

2\. Line 246, "Fe 17.5 μmol (1 mg)/day"

Line 275, "10 μmol (1 mg)/day"

Line 296, "10 mmol (1 mg)/day." Which is correct?

"Fe 17.5 μmol (1 mg)/day" is correct. The others have been changed.

3\. Table 3, "Iron given 1 year before death (μmol L)." "Total iron volume during inpatient infusion (μmol L) "

Please explain the unit "μmol L". I think total iron amount administerd can be described as mass rather than concentration.

Thank you for your comment. This was also an error. The "L" has been deleted.

4\. In table 4 and 5, why did total cohort including patients without iron staining in the liver show high ferritin level?

In patients with chronic inflammatory disease, the higher ferritin levels are likely to be caused by problems in iron metabolism rather than a reflection of iron deposition from TPN. In the present study, all patients were hospitalised and at the end stages of their lives. We believe that the ferritin levels in these particular patients are not related to iron deposition in the liver. We have therefore included an explanation for this in the Discussion section and have added reference 27.

P. 20; Lines 325-331.

However, the ferritin level was higher in some patients without iron staining than those with iron staining. In patients with chronic inflammatory diseases, higher ferritin levels are more likely to be caused by problems in iron metabolism whether there is a lot of iron or not, that is, regardless of the accumulation of iron \[27\]. In the present study, all patients had been hospitalized with terminal diseases, and their median age was 85 years. Among some of these patients, the ferritin level may not be related to iron deposition in the liver.

5\. Multivariate analysis can be performed using factors in Table 3 and 4.

6\. Please add the factors of TPN and iron infusion in Table 5.

Based on your suggestions in comments \#5 and \#6, we have analysed factors associated with iron staining using logistic regression models. These results are presented in Table 6 of the Results section with the subheading "Factors associated with iron staining."

P. 14; Lines 218-224.

Logistic regression analysis revealed that male sex (odds ratio \[OR\], 4.119; 95% confidence interval \[CI\], 1.773-9.566) and iron in post-mortem serum (OR, 1.025; 95% CI, 1.010-1.041) were factors associated with iron staining if the volume of TPN was included in the adjusted variables. If the volume of TPN was excluded from this analysis, UIBC in post-mortem serum (OR, 1.014; 95% CI, 1.003-1.022) and administration of TPN (OR, 3.586; 95% CI, 1.664-7.732) were factors significantly associated with iron staining.

10.1371/journal.pone.0237104.r003
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Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

Reviewer \#3: (No Response)
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#3: Partly
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3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes
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Reviewer \#3: I Don\'t Know
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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Reviewer \#3: It is a very interesting paper that warns of iron overdose due to the iron content in high calorie infusion formulations. It is unknown how many people were receiving iron drugs for anemia. Give some comments about iron drugs in discussion section.

\*\*\*\*\*\*\*\*\*\*
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**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes: Hidehiro Kamezaki
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Point-by-point response to reviewers' comments

Thank you very much for your time and valuable feedback. We have carefully considered your comments and suggestions and have revised our manuscript accordingly. We have included our responses to the reviewers' comments below. For clarity, the reviewer's comments are shown in blue and our responses are shown in black.

Reviewer reports:

Reviewer \#1: Thank you for revising the problem.

The manuscript has been much improved according to the review comments. Furthermore, the second version had been enhanced by adding an analysis of predictable markers for iron deposition using multivariate analysis.

Thank you very much.

Reviewer \#3: It is a very interesting paper that warns of iron overdose due to the iron content in high calorie infusion formulations. It is unknown how many people were receiving iron drugs for anemia. Give some comments about iron drugs in discussion section.

Thank you very much for your comments. According to the medical record, none of the patients were receiving iron drug for the anemia. Basically, the hemoglobin level of the elderly is often lower than the normal value, but this is because of iron utilization disorder in the terminal elderly. The attending physician did not adjust the iron preparation due to some fluctuation in hemoglobin. In addition, they had not checked strictly the serum iron, unsaturated iron binding capacity, and ferritin level. The iron agent contained in daily TPN is the purpose of daily iron supplementation rather than the purpose of improvement. In addition, there were no cases where iron was administered to improve the anemia. We added and described these points.

P. 18; Lines 290-294.

In this study, haemoglobin level of many cases was a little below the normal level. But none of the cases had intensive intravenous iron administration for therapeutic purposes under the diagnosis of iron deficiency anemia. In almost all cases, an all-in-one bag TPN formulation containing a mineral component (iron dose of 1.1 mg/bag) was used for daily iron supplementation.

After checked in-house

1\. Please ensure that you refer to Table 6 in your text as, if accepted, production will need this reference to link the reader to the Table.

P. 14; Lines 221, and 224

Thank you very much for the advice. I have referred to Table 6 in text at P.14; Lines 221, and 224.

10.1371/journal.pone.0237104.r005
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